Hims & Hers Health (HIMS) saw its shares surge in the last session with trading volume being higher than average. The latest ...

Hims & Hers Health, Inc. (HIMS) concluded the recent trading session at $60.30, signifying a +1.88% move from its prior day's close.

Hims & Hers wants to keep on selling a compounded version of Ozempic. And it's channeling anti-establishment vibes to make its case.

When it comes to achieving healthy body weight, some men might look to what’s average and use that as their goal. For ...

Melissa Baird, the Chief Operating Officer of Hims & Hers Health, Inc. (NYSE:HIMS), has recently sold a significant portion of her holdings in the company. According to a recent SEC filing, Baird sold ...

Novo Nordisk (NVO) stock took a hit this week, after a Super Bowl ad highlighted a growing challenge to the company’s ...

One developer of a weight loss medication, clinical-stage biotech Structure Therapeutics ( GPCR 0.16%), was a victim of a ...

Pfizer clinches the top spot in the competitive 2025 Super Bowl ad race, promising groundbreaking visibility during the big ...

From mind-blowing tidal surges to the Earth moving, clichés abound when it comes to orgasms. But we’re not all in the throes of ecstasy. According to digital health platform Hims & Hers’s 2023 report, ...

After a telehealth company's Super Bowl commercial sparked nationwide debate about pharmaceutical safety and advertising, one DSO executive is reflecting on what the controversy means for patient care ...